Liraglutide for Insulin Resistance

Phase-Based Progress Estimates
3
Effectiveness
3
Safety
Insulin Resistance
Liraglutide - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

In this research study, investigators will test the effects of an approved medication for diabetes,Liraglutide, to reduce insulin resistance that develops from eating a diet high in saturated fats.

Treatment Effectiveness

Effectiveness Progress

3 of 3
This is further along than 93% of similar trials

Study Objectives

1 Primary · 9 Secondary · Reporting Duration: 3 weeks

3 weeks
Adipose tissue arteriole function (vasodilation measurement)
Adipose tissue inflammation measures (e.g., interleukin (IL)-6, and -8, adiponectin, TNF-alpha, nuclear factor-kappa b, gene and protein expression)
Changes in adipose tissue insulin signaling pathway activation (compare insulin signaling pathway activity (e.g., Akt and insulin receptor phosphorylation)
Changes in skeletal muscle insulin signaling pathway
Postprandial changes in glucose metabolism (total and incremental area under the curve differences in glucose, insulin and glucagon)
Postprandial lipid changes (area under the curve difference in triglyceride,total apolipoprotein B100, apolipoprotein B48, and apolipoprotein C3.
Skeletal muscle inflammation measures (e.g., IL-6,8, TNF-alpha, nuclear factor-kappa b gene and protein expression)
Whole Body Insulin Sensitivity (insulin suppression test)
skeletal muscle tissue lipid intermediates (e.g., ceramide, diacylglycerol, acylcarnitine concentrations)
subcutaneous adipose tissue lipid intermediates (e.g., ceramide, diacylglycerol, acylcarnitine concentrations)

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Side Effects for

Liraglutide
29%nausea
This histogram enumerates side effects from a completed 2017 Phase 4 trial (NCT02014740) in the Liraglutide ARM group. Side effects include: nausea with 29%.

Trial Design

2 Treatment Groups

Liraglutide
1 of 2
Sugar pill
1 of 2

Experimental Treatment

Non-Treatment Group

35 Total Participants · 2 Treatment Groups

Primary Treatment: Liraglutide · Has Placebo Group · Phase 4

Liraglutide
Drug
Experimental Group · 1 Intervention: Liraglutide · Intervention Types: Drug
Sugar pill
Drug
PlaceboComparator Group · 1 Intervention: Sugar Pill · Intervention Types: Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Liraglutide
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 3 weeks

Who is running the clinical trial?

Phoenix VA Health Care SystemLead Sponsor
12 Previous Clinical Trials
1,440 Total Patients Enrolled
1 Trials studying Insulin Resistance
300 Patients Enrolled for Insulin Resistance
Novo Nordisk A/SIndustry Sponsor
1,392 Previous Clinical Trials
2,293,958 Total Patients Enrolled
4 Trials studying Insulin Resistance
127 Patients Enrolled for Insulin Resistance
Peter D Reaven, MDPrincipal InvestigatorCarl T. Hayden Medical Research Foundation
5 Previous Clinical Trials
1,634 Total Patients Enrolled
1 Trials studying Insulin Resistance
300 Patients Enrolled for Insulin Resistance

Eligibility Criteria

Age 18+ · All Participants · 4 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 3rd, 2021

Last Reviewed: November 29th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.